These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 16741917)
1. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Bajgelman MC; Strauss BE Prostate; 2006 Sep; 66(13):1455-62. PubMed ID: 16741917 [TBL] [Abstract][Full Text] [Related]
2. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Gurova KV; Rokhlin OW; Budanov AV; Burdelya LG; Chumakov PM; Cohen MB; Gudkov AV Cancer Res; 2003 Jun; 63(11):2905-12. PubMed ID: 12782597 [TBL] [Abstract][Full Text] [Related]
3. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Isaacs WB; Carter BS; Ewing CM Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816 [TBL] [Abstract][Full Text] [Related]
4. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890 [TBL] [Abstract][Full Text] [Related]
5. Stable expression of temperature-sensitive p53: a suitable model to study wild-type p53 function in pancreatic carcinoma cells. Nuevemann D; Christgen M; Ungefroren H; Kalthoff H Oncol Rep; 2006 Sep; 16(3):575-9. PubMed ID: 16865258 [TBL] [Abstract][Full Text] [Related]
6. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription. Torosyan Y; Dobi A; Naga S; Mezhevaya K; Glasman M; Norris C; Jiang G; Mueller G; Pollard H; Srivastava M Cancer Res; 2006 Oct; 66(19):9609-16. PubMed ID: 17018618 [TBL] [Abstract][Full Text] [Related]
7. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Fujita Y; Kojima K; Hamada N; Ohhashi R; Akao Y; Nozawa Y; Deguchi T; Ito M Biochem Biophys Res Commun; 2008 Dec; 377(1):114-9. PubMed ID: 18834855 [TBL] [Abstract][Full Text] [Related]
8. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124. Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349 [TBL] [Abstract][Full Text] [Related]
9. p53 controls hPar1 function and expression. Salah Z; Haupt S; Maoz M; Baraz L; Rotter V; Peretz T; Haupt Y; Bar-Shavit R Oncogene; 2008 Nov; 27(54):6866-74. PubMed ID: 18820708 [TBL] [Abstract][Full Text] [Related]
10. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Brazda V; Muller P; Brozkova K; Vojtesek B Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499 [TBL] [Abstract][Full Text] [Related]
11. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250 [TBL] [Abstract][Full Text] [Related]
13. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway. Zhang AL; Russell PJ; Knittel T; Milross C Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933 [TBL] [Abstract][Full Text] [Related]
15. The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53. Tam CW; Liu VW; Leung WY; Yao KM; Shiu SY Cancer Lett; 2008 Nov; 271(1):64-80. PubMed ID: 18639375 [TBL] [Abstract][Full Text] [Related]
16. DNA binding and selective gene induction by different forms of the p53 protein. Mayelzadeh F; Martinez JD Oncogene; 2007 May; 26(21):2955-63. PubMed ID: 17130840 [TBL] [Abstract][Full Text] [Related]
17. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253 [TBL] [Abstract][Full Text] [Related]
18. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Kelly JA; Lucia MS; Lambert JR Cancer Lett; 2009 May; 277(1):38-47. PubMed ID: 19100681 [TBL] [Abstract][Full Text] [Related]
19. Transcription regulation by mutant p53. Weisz L; Oren M; Rotter V Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429 [TBL] [Abstract][Full Text] [Related]
20. [DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines]. Wang CY; Sun SK; Fu WJ; Song T; Cai W; Gao JP; Hong BF; Wang XX; Wang H Zhonghua Nan Ke Xue; 2008 Aug; 14(8):685-9. PubMed ID: 18817338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]